|Bid||0.00 x 1300|
|Ask||0.00 x 800|
|Day's Range||59.25 - 61.18|
|52 Week Range||36.92 - 86.96|
|Beta (3Y Monthly)||1.97|
|PE Ratio (TTM)||45.68|
|Earnings Date||Nov 6, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||75.00|
ANI Pharmaceuticals could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) will present on December 3, 2019 at the Evercore ISI HealthCONx Conference in Boston, Massachusetts. Arthur Przybyl, President and CEO, Robert Schrepfer, Senior Vice President Business Development & Specialty Sales, and Mark Ginski, Vice President Cortrophin Product Development, will present at 10:15 AM ET on Tuesday, December 3, 2019. The presentation will be webcast live at http://wsw.com/webcast/evercore4/anip/. The live webcast will be archived and available through the prior link for 90 days following the presentation.
Today we'll do a simple run through of a valuation method used to estimate the attractiveness of ANI Pharmaceuticals...
ANI (ANIP) delivered earnings and revenue surprises of -16.89% and -10.25%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
BAUDETTE, Minn. , Nov. 6, 2019 /PRNewswire/ -- For the third quarter 2019: Net revenues of $51.3 million , an increase of 1% versus prior year GAAP net income of $3.9 million and diluted GAAP earnings ...
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Nov. 5.) Agile Therapeutics Inc (NASDAQ: AGRX ) (follow-on ...
BAUDETTE, Minn., Oct. 31, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (ANIP) today announced that its partner Pharmaceutics International Inc. (Pii) has received FDA approval of a Prior Approval Supplement for Bretylium Tosylate Injection, USP 500mg/10ml (50mg/ml). ANI plans to launch this currently unavailable drug in December, introducing this critical drug for the treatment of ventricular fibrillation and life-threatening ventricular arrhythmias, such as ventricular tachycardia.
BAUDETTE, Minn. , Oct. 30, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) announced today that the Company plans to release its third quarter and year-to-date 2019 financial results on Wednesday, ...
ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BAUDETTE, Minn. , Oct. 29, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP), an experienced specialty pharmaceutical and contract development & manufacturing organization ...
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. Insider Monkey finished processing more than 730 13F filings submitted by hedge funds and prominent investors. These filings show these funds' portfolio positions as of June […]
Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of...
The results indicate that ANI's Cortrophin® Gel (80 units/mL) is effective for its intended use. In addition, the clinical data demonstrate that ANI's modernized Cortrophin® Gel (80 units/mL) drug product has a cortisol response profile consistent with that observed in historical scientific literature that evaluated Cortrophin® Gel (44 units/mL) drug product manufactured in the 1960s (Brombacher et. al, 1969).
BAUDETTE, Minn., Oct. 2, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (ANIP) today announced the launch of Aspirin and Extended Release Dipyridamole Capsules, 25mg/200mg (the generic equivalent of Aggrenox®). This launch represents ANI's fifth generic product introduction in 2019. ANI acquired the rights to launch this drug in an acquisition executed in 2018. As part of that acquisition, ANI entered into a supply agreement for Aspirin and Extended Release Dipyridamole Capsules whereby ANI receives drug product, packaged in the ANI label, starting on October 1, 2019 and ending no later than March 1, 2021. ANI estimates that the current annual U.S. market for Aspirin and Extended Release Dipyridamole Capsules is approximately $80 million, based on Iqvia data. There are currently six suppliers of this drug in the U.S. market.
Mangrove Partners was founded by Nathaniel August, who is also the fund’s president and portfolio manager. Mr August holds a B.A. from Brown University, and prior to launching his fund, he worked as a director at White Eagle Partners, as an Investment Analyst at K Capital Partners, as a Senior Analyst at Brahman Capital Partners, […]
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
BAUDETTE, Minn., Sept. 11, 2019 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (ANIP) today announced the launch of Vancomycin HCl for Oral Solution, 250mg per 5mL (the generic equivalent to ANI's Vancocin® for Oral Solution). To facilitate ease of administration the drug now includes a mixed berry taste, can be administered via nasogastric tube and does not contain any ingredients made with gluten-containing grain (wheat, barley, rye). The dye-free product is delivered in a single bottle format requiring simple reconstitution and offers dosing flexibility achieved through the availability of three different size bottles: 80mL, 150mL and 300mL. ANI estimates that the current annual U.S. vancomycin market is approximately $450 million. Arthur S. Przybyl, ANI's President and CEO stated, "This launch represents yet another successful re-commercialization for ANI of a previously discontinued drug and is our fourth generic product introduction in 2019. Our launch of Vancomycin for Oral Solution addresses an unmet need in the treatment of staph and C-diff infections and provides patients, physicians and pharmacists with a convenient, FDA-approved oral solution of vancomycin in addition to the currently available capsule and injectable forms. We are supporting this launch with an awareness campaign that leverages the existing virtual marketing infrastructure that we use to support our brand portfolio.
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
ANI (ANIP) delivered earnings and revenue surprises of 11.63% and -2.24%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?